R-GemOx方案治疗复发难治性B细胞淋巴瘤有效性和安全性的单臂Meta分析  

Efficacy and safety of R-GemOx regimen for relapsed refractory B-cell lymphoma:a single-arm Meta analysis

作　　者：黄国鑫 曹启龙[3] 田建洲 艾金伟 屈高静 裴斌 Guo-Xin HUANG;Qi-Long CAO;Jian-Zhou TIAN;Jin-Wei AI;Gao-Jing QU;Bin PEI(Center of Evidence-based Medicine,Xiangyang No.1 People’s Hospital,Hubei University of Medicine,Xiangyang 441000,Hubei Province,China;School of Public Health,Hubei University of Medicine,Shiyan 442000,Hubei province,China;Qingdao Haier Biotech Co.,Ltd.,Qingdao 266000,Shandong province,China;Renmin Hospital,Hubei University of Medicine,Shiyan 442000,Hubei province,China)

机构地区：[1]湖北医药学院附属襄阳市第一人民医院循证医学中心,湖北襄阳441000 [2]湖北医药学院公共卫生与健康学院,湖北十堰442000 [3]青岛海尔生物科技有限公司,山东青岛266000 [4]湖北医药学院附属十堰市人民医院,湖北十堰442000

出　　处：《医学新知》2023年第6期438-449,共12页New Medicine

基　　金：湖北省“323”攻坚行动襄阳市第一人民医院重点专项科研基金(XYY2022-323);襄阳市第一人民医院科技创新项目(XYY2023SD06)。

摘　　要：目的系统评价利妥昔单抗联合吉西他滨和奥沙利铂(R-GemOx)方案治疗复发难治性B细胞淋巴瘤的有效性和安全性,为临床用药提供依据。方法系统检索PubMed、Embase、CNKI、CBM、VIP及万方数据库中关于R-GemOx方案治疗复发难治性B细胞淋巴瘤的试验性研究和观察性研究,检索时限为各数据库建库至2022年9月13日。提取文献数据并行质量评价,运用R软件进行Meta分析。结果共纳入13篇文献,涉及526例复发难治性B细胞淋巴瘤患者。Meta分析结果显示,患者完全缓解率为37.48%[95%CI(30.25%,46.45%)],部分缓解率为28.62%[95%CI(21.06%,38.90%)],疾病稳定率为12.03%[95%CI(7.03%,17.93%)],疾病进展率为21.20%[95%CI(15.73%,27.22%)],总缓解率为62.19%[95%CI(52.25%,74.02%)],临床获益率为79.40%[95%CI(72.49%,85.62%)]。安全性方面,以血液系统毒性、消化系统毒性和神经系统毒性为主。结论R-GemOx方案治疗复发难治性B细胞淋巴瘤是一种有效、药物毒性可耐受的治疗方案。Objective Systematic evaluation of the efficacy and safety of the Rituximab plus gemcitabine and oxaliplatin(R-GemOx)regimen for the treatment of relapsed refractory B-cell lymphoma.Methods The PubMed,Embase,CNKI,CBM,VIP and Wan-Fang databases were systematically searched for experimental and observational studies on the R-GemOx regimen for relapsed refractory B-cell lymphoma.The search time frame is from the establishment of each database to September 13,2022.After extracting the literature and evaluating the quality of the literature in parallel,Meta-analysis was performed using R(4.2.1)software.Results A total of 526 cases of relapsed refractory B-cell lymphoma were included in 13 studies.Meta-analysis showed that the complete response rate(CRR)was 37.48%[95%CI(30.25%,46.45%)];partial response rate(PRR)was 28.62%[95%CI(21.06%,38.90%)];stable disease rate(SDR)was 12.03%[95%CI(7.03%,17.93%)];progressive disease rate(PDR)was 21.20%[95%CI(15.73%,27.22%)];over response rate(ORR)was 62.19%[95%CI(52.25%,74.02%)];clinical benefit rate(CBR)was 79.40%[95%CI(72.49%,85.62%)].Safety was dominated by hematological system toxicity,digestive system toxicity and nervous system toxicity.Conclusion The R-GemOx regimen for relapsed refractory B-cell lymphoma is an effective treatment option with tolerable drug toxicity.

关 键 词：R-GemOx方案 复发难治性B细胞淋巴瘤 单臂Meta分析 有效性 安全性 

分 类 号：R733.1[医药卫生—肿瘤]